Summary
Pharma Deprée is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €257,179 and a net result of €67,217. Equity is growing by about 22% per year across the filed financial years. Its solvency ranks better than 29% of 6,673 sector peers (NACE 64, financial year 2025). The company has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- PHARMA DEPRÉE
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Bepaalde of onbepaalde termijn, één of meer bestuurders” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- “Artikel 19 Jaarlijks wordt een algemene vergadering gehouden in de zetel van de vennootschap op de voorlaatste maandag van juni om twintig…” (deed in Dutch)